Is Phesgo (pertuzumab and trastuzumab) administered every 3 weeks?

From the Guidelines

Phesgo is given every 3 weeks, as it is a fixed-dose combination of pertuzumab and trastuzumab, which are administered on the same schedule as their intravenous forms, with pertuzumab and trastuzumab given every 3 weeks, as seen in the guidelines for HER-2 amplification treatment 1. The dosing schedule for Phesgo is based on the standard treatment regimen for pertuzumab and trastuzumab, which involves an initial dose followed by maintenance doses every 3 weeks.

• The initial dose of pertuzumab is 840mg, and trastuzumab is 8 mg/kg, with maintenance doses of 420mg and 6 mg/kg, respectively, given every 3 weeks 1.
• This schedule allows for consistent therapeutic drug levels while minimizing patient burden compared to more frequent dosing.
• Phesgo is used in the treatment of HER2-positive breast cancer, and its administration as a subcutaneous injection takes approximately 5-8 minutes, which is significantly shorter than the intravenous infusions of the individual medications. Key points to consider when administering Phesgo include:
• The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf
• The standard dosing schedule of every 3 weeks
• The importance of maintaining consistent therapeutic drug levels to ensure optimal efficacy
• The reduced patient burden compared to more frequent dosing or intravenous infusions.

From the FDA Drug Label

The initial dose of PERJETA is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes PERJETA should be administered every 3 weeks for 3 to 6 cycles as part of one of the following treatment regimens for early breast cancer PERJETA should be administered in combination with trastuzumab or trastuzumab hyaluronidase-oysk every 3 weeks for a total of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity, whichever occurs first, as part of a complete regimen for early breast cancer

Phesgo administration schedule: Phesgo, which is a combination of pertuzumab and trastuzumab, is administered every 3 weeks.

• The dose is administered subcutaneously over approximately 2 to 5 minutes.
• It is given in combination with chemotherapy. 2

From the Research

Administration of Phesgo

• Phesgo is a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, which can be administered every 3 weeks 3, 4.
• The administration of Phesgo every 3 weeks is supported by studies such as the FeDeriCa trial, which compared the pharmacokinetics, efficacy, and safety of the fixed-dose subcutaneous formulation to intravenous pertuzumab plus trastuzumab in patients with HER2-positive early breast cancer 4.
• Another study, PERTAIN, also administered pertuzumab and trastuzumab every 3 weeks, with or without chemotherapy, to patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer 5.

Dosage and Treatment

• The dosage of Phesgo is a fixed-dose combination of 1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL, administered every 3 weeks 4.
• Phesgo can be administered with chemotherapy, and the treatment regimen may vary depending on the patient's specific condition and response to treatment 3, 5, 4.

Safety and Efficacy

• The safety and efficacy of Phesgo have been evaluated in several studies, including the FeDeriCa trial and the PERTAIN study, which demonstrated that Phesgo is non-inferior to intravenous pertuzumab plus trastuzumab in terms of pharmacokinetics and efficacy 3, 5, 4.
• The most common adverse events associated with Phesgo are similar to those associated with intravenous pertuzumab plus trastuzumab, including neutropenia, decreased neutrophil count, febrile neutropenia, diarrhea, and decreased white blood cell count 4.